PHILADELPHIA - Brian Strom, MD, Chair and Professor of Biostatistics and Epidemiology and Director of the Center for Clinical Epidemiology & Biostatistics, has been named Editor-in-Chief of Pharmacoepidemiology and Drug Safety, the official journal of the International Society for Pharmacoepidemiology, starting September 1.

 “As Editor-in-Chief, my goals are to develop the journal into the premier journal for the field in the world,” says Strom. His duties include determining policy and papers accepted to the journal. He will hold the position until December of 2012, renewable thereafter. 

The journal publishes papers on drug safety, pharmaceutical risk management, and the new field of comparative effectiveness research. Particular areas of interest include: design, results, analysis and interpretation of post-marketing surveillance and other studies looking at specific drugs, populations and outcomes; methods for detection and evaluation of drug-associated adverse events; assessments of risk and benefit in drug therapy; patterns of drug utilization; and the relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines.

Strom's clinical and research training is in general internal medicine, clinical pharmacology, and epidemiology. He has authored over 500 publications, including peer-reviewed articles, editorials, reviews, chapters, and books.

Sean Hennessy, PharmD, PhD, Associate Professor of Epidemiology and Pharmacology and Director of the Ambulatory Drug Use & Effects Program will be assuming the position of Regional Editor for the Americas for the journal, also starting September 1. Hennessy’s primary field of interest is pharmacoepidemiology. He is currently leading National Institutes of Health-funded studies on drug-induced sudden death and ventricular arrhythmia, and on the clinical importance of drug-drug interactions.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.

Share This Page: